Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Common Stock (NQ: XOMA )

20.50 -0.66 (-3.13%)
Streaming Delayed Price Updated: 3:52 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about XOMA Royalty Corporation - Common Stock

< Previous 1 2 3 Next >
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
From Brodsky & Smith LLC
Via GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023
XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Recap: XOMA Q4 Earnings
Via Benzinga
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
From XOMA Corporation
Via GlobeNewswire
XOMA's Return On Capital Employed Insights
Via Benzinga
XOMA to Present at Upcoming Investor Conferences in March
From XOMA Corporation
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
From Brodsky & Smith LLC
Via GlobeNewswire
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024. 
Via Benzinga
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio 
From XOMA Corporation
Via GlobeNewswire
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
From XOMA Corporation
Via GlobeNewswire
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024 
From XOMA Corporation
Via GlobeNewswire
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
From XOMA Corporation
Via GlobeNewswire
XOMA Announces Stock Repurchase Program of up to $50 Million
Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return 
From XOMA Corporation
Via GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
From XOMA Corporation
Via GlobeNewswire
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
From XOMA Corporation
Via GlobeNewswire
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024 
From XOMA Corporation
Via GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
From XOMA Corporation
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  During Monday, 102 stocks hit new 52-week lows. 
Via Benzinga
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
From XOMA Corporation
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 57 companies reached new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
XOMA Added to the Russell 2000® and Russell 3000® Indexes
From XOMA Corporation
Via GlobeNewswire
Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: Analyst
Earlier today, XOMA Corporation (NASDAQ: XOMA) acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol for Niemann-Pick disease type C, and... 
Via Benzinga
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹ 
From XOMA Corporation
Via GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
Recap: XOMA Q1 Earnings
XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,... 
Via Benzinga
XOMA: Q1 Earnings Insights
XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.